Teleflex Incorporated (NYSE:TFX) Shares Sold by Rowlandmiller & PARTNERS.ADV

Rowlandmiller & PARTNERS.ADV lowered its stake in shares of Teleflex Incorporated (NYSE:TFX) by 1.5% in the third quarter, HoldingsChannel reports. The firm owned 8,528 shares of the medical technology company’s stock after selling 130 shares during the quarter. Rowlandmiller & PARTNERS.ADV’s holdings in Teleflex were worth $2,109,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in TFX. Canada Pension Plan Investment Board bought a new stake in Teleflex during the 2nd quarter valued at $42,000. GAMMA Investing LLC raised its stake in Teleflex by 131.1% during the 3rd quarter. GAMMA Investing LLC now owns 171 shares of the medical technology company’s stock valued at $42,000 after acquiring an additional 97 shares in the last quarter. Versant Capital Management Inc raised its stake in shares of Teleflex by 20,700.0% in the 2nd quarter. Versant Capital Management Inc now owns 208 shares of the medical technology company’s stock worth $44,000 after buying an additional 207 shares in the last quarter. Blue Trust Inc. raised its stake in shares of Teleflex by 78.2% in the 2nd quarter. Blue Trust Inc. now owns 212 shares of the medical technology company’s stock worth $48,000 after buying an additional 93 shares in the last quarter. Finally, Quarry LP bought a new stake in shares of Teleflex in the 2nd quarter worth $48,000. Institutional investors and hedge funds own 95.62% of the company’s stock.

Teleflex Price Performance

Shares of NYSE TFX opened at $235.62 on Friday. The stock has a market capitalization of $11.10 billion, a price-to-earnings ratio of 42.30, a PEG ratio of 2.15 and a beta of 1.16. The business has a 50-day moving average of $241.19 and a 200-day moving average of $223.48. The company has a debt-to-equity ratio of 0.36, a current ratio of 2.58 and a quick ratio of 1.44. Teleflex Incorporated has a fifty-two week low of $177.63 and a fifty-two week high of $257.85.

Teleflex (NYSE:TFX) last posted its quarterly earnings results on Thursday, August 1st. The medical technology company reported $3.42 EPS for the quarter, topping analysts’ consensus estimates of $3.33 by $0.09. Teleflex had a return on equity of 14.51% and a net margin of 8.76%. The business had revenue of $749.70 million during the quarter, compared to analysts’ expectations of $762.98 million. During the same quarter last year, the company posted $3.41 earnings per share. Teleflex’s quarterly revenue was up .9% on a year-over-year basis. As a group, sell-side analysts predict that Teleflex Incorporated will post 13.97 earnings per share for the current fiscal year.

Teleflex Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, September 16th. Stockholders of record on Thursday, August 15th were given a $0.34 dividend. The ex-dividend date was Thursday, August 15th. This represents a $1.36 dividend on an annualized basis and a dividend yield of 0.58%. Teleflex’s payout ratio is 24.42%.

Insider Activity

In other news, Director Stuart A. Randle sold 2,674 shares of Teleflex stock in a transaction that occurred on Friday, August 16th. The shares were sold at an average price of $238.93, for a total value of $638,898.82. Following the completion of the sale, the director now directly owns 5,496 shares in the company, valued at approximately $1,313,159.28. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 1.43% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on TFX. Piper Sandler upgraded Teleflex from a “neutral” rating to an “overweight” rating and lifted their target price for the stock from $205.00 to $245.00 in a report on Monday, July 1st. Truist Financial lifted their target price on Teleflex from $247.00 to $255.00 and gave the stock a “hold” rating in a report on Monday, October 14th. Stephens lifted their target price on Teleflex from $275.00 to $290.00 and gave the stock an “overweight” rating in a report on Friday, August 2nd. Finally, Royal Bank of Canada lifted their price target on Teleflex from $260.00 to $275.00 and gave the company an “outperform” rating in a report on Tuesday, October 8th. Three investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $268.86.

Teleflex Profile

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.